According to MannKind Corporation, Brazil’s Drug Market Regulation Chamber (CMED) has approved the proposed pricing for Afrezza inhaled insulin, and the Afrezza DPI is set to launch in Brazil within the next week. The Brazilian Health Regulatory Agency (ANVISA) approved Afrezza for the treatment of diabetes in June 2019.
In June 2017, MannKind announced that it had signed a distribution agreement for Afrezza with Biomm, which will market the inhaler throughout Brazil.
MannKind distributes Afrezza itself in the US and in May 2018 announced a deal with Cipla for distribution of the drug in India. In July 2018, the company announced that Tanner Pharma Group would distribute Afrezza in regions outside of the US where it was not already approved.
Read the MannKind Corporation press release.
